发布求助
文献互助 智能选刊 最新文献

European Cardiology Review最新文献

筛选
英文 中文
When Should We Start Sodium-Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention. 我们应该在心力衰竭患者中何时开始使用钠-葡萄糖共转运蛋白抑制剂？早期干预的重要性。
IF 3
European Cardiology Review Pub Date : 2023-06-07 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2022.62
Moritake Iguchi, Hiromichi Wada, Felipe Martínez, Koji Hasegawa
{"title":"When Should We Start Sodium-Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention.","authors":"Moritake Iguchi, Hiromichi Wada, Felipe Martínez, Koji Hasegawa","doi":"10.15420/ecr.2022.62","DOIUrl":"10.15420/ecr.2022.62","url":null,"abstract":"www.ECRjournal.com Sodium–glucose co-transporter (SGLT2) inhibitors were primarily developed as anti-diabetic drugs to increase the excretion of glucose in the urine. However, SGLT2 inhibitors have been reported to have multifactorial effects, such as renal protection and improvement of myocardial energy metabolism and anaemia symptoms, which may exert protection against progression of heart failure beyond their mere diuretic action.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e41"},"PeriodicalIF":3.0,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/cb/ecr-18-e41.PMC10345959.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus. 2022 年欧洲心脏病学会心脏病肿瘤指南聚焦。
IF 3.2
European Cardiology Review Pub Date : 2023-04-21 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2022.63
David G Gent, Dobson Rebecca
{"title":"The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus.","authors":"David G Gent, Dobson Rebecca","doi":"10.15420/ecr.2022.63","DOIUrl":"10.15420/ecr.2022.63","url":null,"abstract":"<p><p>The expansion of the therapeutic armamentarium available to oncologists and haematologists has led to a significant improvement in cancer survival; however, many of the available treatments carry a risk of toxicity to the heart. Cardio-oncology has emerged as a rapidly developing subspeciality dedicated to improving the cardiovascular care of patients before, during and after cancer treatment. The 2022 European Society of Cardiology guidelines on cardio-oncology provide a comprehensive overview of best-practice recommendations for cardiovascular care aimed at healthcare professionals treating cancer patients. The main focus of the guidelines is to ensure patients can complete their cancer treatment without significant cardiotoxicity and the correct follow-up for the first 12 months following treatment and beyond is instituted. The guidelines provide harmonisation of baseline risk stratification and toxicity definitions and encompass recommendations for all the major classes of therapy used in modern oncology and haematology. This review summarises the key points from the guidelines document.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e16"},"PeriodicalIF":3.2,"publicationDate":"2023-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/1b/ecr-18-e16.PMC10316349.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10179307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fulminant Myocarditis: When One Size Does Not Fit All - A Critical Review of the Literature. 暴发性心肌炎：当 "一刀切 "无法解决所有问题时--文献综述。
IF 3.2
European Cardiology Review Pub Date : 2023-04-20 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2022.54
Andrea Silvio Giordani, Anna Baritussio, Cristina Vicenzetto, Maria Grazia Peloso-Cattini, Elena Pontara, Elisa Bison, Chiara Fraccaro, Cristina Basso, Sabino Iliceto, Renzo Marcolongo, Alida Linda Patrizia Caforio
{"title":"Fulminant Myocarditis: When One Size Does Not Fit All - A Critical Review of the Literature.","authors":"Andrea Silvio Giordani, Anna Baritussio, Cristina Vicenzetto, Maria Grazia Peloso-Cattini, Elena Pontara, Elisa Bison, Chiara Fraccaro, Cristina Basso, Sabino Iliceto, Renzo Marcolongo, Alida Linda Patrizia Caforio","doi":"10.15420/ecr.2022.54","DOIUrl":"10.15420/ecr.2022.54","url":null,"abstract":"<p><p>Fulminant myocarditis, rather than being a distinct form of myocarditis, is instead a peculiar clinical presentation of the disease. The definition of fulminant myocarditis has varied greatly in the last 20 years, leading to conflicting reports on prognosis and treatment strategies, mainly because of varied inclusion criteria in different studies. The main conclusion of this review is that fulminant myocarditis may be due to different histotypes and aetiologies that can be diagnosed only by endomyocardial biopsy and managed by aetiology-directed treatment. This life-threatening presentation requires rapid, targeted management both in the short term (mechanical circulatory support, inotropic and antiarrhythmic treatment and endomyocardial biopsy) and in the long term (including prolonged follow-up). Fulminant presentation has also recently been identified as a risk factor for worsened prognosis, even long after the resolution of the acute phase of myocarditis.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e15"},"PeriodicalIF":3.2,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/51/ce/ecr-18-e15.PMC10316338.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10179312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ESC Congress 2022 Imaging Highlights. 2022 年 ESC 大会成像亮点。
IF 3.2
European Cardiology Review Pub Date : 2023-04-06 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2022.46
Valentina O Puntmann, Silvia Valbuena-López
{"title":"ESC Congress 2022 Imaging Highlights.","authors":"Valentina O Puntmann, Silvia Valbuena-López","doi":"10.15420/ecr.2022.46","DOIUrl":"10.15420/ecr.2022.46","url":null,"abstract":"<p><p>Cardiac imaging is an ever-evolving area, with imaging parameters and application in constant re-evaluation. This was reflected in many imaging debates and by the increased number of scientific contributions at the European Society of Cardiology Congress in 2022. While clinical trials tried to answer clinical questions related to the performance of different imaging modalities, many high-quality presentations focused on new imaging biomarkers in different scenarios, such as heart failure with preserved ejection fraction, valvular heart disease or long COVID. This highlights the need for the translation of cardiac imaging technology from research interests towards established measures of clinical practice.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e12"},"PeriodicalIF":3.2,"publicationDate":"2023-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/2c/ecr-18-e12.PMC10316344.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9793288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on the ESC Guidelines 2022 for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. 对2022年ESC室性心律失常患者管理和预防心源性猝死指南的评论
IF 3
European Cardiology Review Pub Date : 2023-02-01 DOI: 10.15420/ecr.2022.48
David Calvo Cuervo
{"title":"Comment on the ESC Guidelines 2022 for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.","authors":"David Calvo Cuervo","doi":"10.15420/ecr.2022.48","DOIUrl":"https://doi.org/10.15420/ecr.2022.48","url":null,"abstract":"<p><p>The European Society of Cardiology guidelines for the management of sudden cardiac death and ventricular arrhythmias have been updated. Additions and amendments range from clinical management to invasive procedures, and provide new perspectives on integrated management, genetic testing, stratification of risk, arrhythmia ablation and device therapy among others. Significant improvements have been made, which will result in better care for patients and families.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e01"},"PeriodicalIF":3.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/7d/ecr-18-e01.PMC9947934.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9781221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dyspnea in Oncological Patients: a Brain Teaser. 肿瘤患者的呼吸困难:一个脑筋急转弯。
IF 3
European Cardiology Review Pub Date : 2023-02-01 DOI: 10.15420/ecr.2021.62
Kalliopi Keramida, Athanasios Kostoulas
{"title":"Dyspnea in Oncological Patients: a Brain Teaser.","authors":"Kalliopi Keramida,&nbsp;Athanasios Kostoulas","doi":"10.15420/ecr.2021.62","DOIUrl":"https://doi.org/10.15420/ecr.2021.62","url":null,"abstract":"<p><p>Dyspnea is one of the most common symptoms in oncological patients with greater prevalence in lung cancer and advanced disease states. Causes of dyspnea can be directly or indirectly associated with cancer, anti-neoplastic therapies and comorbidities unrelated to cancer. Routine screening of dyspnea is suggested for all oncological patients by using unidimensional, simple scales and multidimensional tools to capture more domains affected by this symptom and to assess the effectiveness of interventions. The first step in the treatment algorithm of dyspnea is the identification of potentially reversible causes; if no specific cause is depicted, symptomatic treatment with non-pharmacological and pharmacological interventions is suggested. Referral to palliative care and continuous palliative sedation are the last resort in patients with a very limited life expectancy of not more than a few days for symptomatic relief and to decrease of the distress of patients and caregivers.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e03"},"PeriodicalIF":3.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/f3/ecr-18-e03.PMC9947930.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10850309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. 雷诺嗪改善保留射血分数的心力衰竭患者舒张功能的疗效:一项系统综述和荟萃分析。
IF 3
European Cardiology Review Pub Date : 2023-02-01 DOI: 10.15420/ecr.2022.10
Desak Ketut Sekar Cempaka Putri, Andrianto Andrianto, Makhyan Jibril Al-Farabi, Pandit Bagus Tri Saputra, Ricardo Adrian Nugraha
{"title":"Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis.","authors":"Desak Ketut Sekar Cempaka Putri,&nbsp;Andrianto Andrianto,&nbsp;Makhyan Jibril Al-Farabi,&nbsp;Pandit Bagus Tri Saputra,&nbsp;Ricardo Adrian Nugraha","doi":"10.15420/ecr.2022.10","DOIUrl":"https://doi.org/10.15420/ecr.2022.10","url":null,"abstract":"<p><p>This article evaluates the efficacy of using ranolazine to improve diastolic performance and exercise capacity in heart failure with preserved ejection fraction. A comprehensive literature review found eight trials where there are no significant difference in peak O2 (p=0.09) and exercise duration (p=0.18) between ranolazine and placebo. The ranolazine group had significantly higher and better diastolic parameters compared to placebo, with a mean difference of 0.45 (95% CI [27.18-39.50]). There were no significant differences for haemodynamic parameters (blood pressure and heart rate) and electrocardiography (QT interval) between ranolazine and placebo. The review found that ranolazine has good wefficacy to improve diastolic performance among heart failure with preserved ejection fraction patients and it does not affect blood pressure, heart rate and rate of ventricular repolarisation (shortening of the QT interval).</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e02"},"PeriodicalIF":3.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/d9/ecr-18-e02.PMC9947928.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10850308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients. 冠心病患者抗凝治疗的展望与未来方向。
IF 3
European Cardiology Review Pub Date : 2023-01-01 DOI: 10.15420/ecr.2022.66
Maki Komiyama, Gheorghe-Andrei Dan, Koji Hasegawa
{"title":"Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients.","authors":"Maki Komiyama,&nbsp;Gheorghe-Andrei Dan,&nbsp;Koji Hasegawa","doi":"10.15420/ecr.2022.66","DOIUrl":"https://doi.org/10.15420/ecr.2022.66","url":null,"abstract":"<p><p>Antiplatelet agents are routinely used to treat patients with chronic atherosclerotic coronary artery disease. Treatment with the addition of a low dose of rivaroxaban as dual-pathway inhibition (DPI) decreases ischaemic events at the expense of increased bleeding. At present, the balance between thrombotic and bleeding risks must be carefully weighed up when considering DPI. However, with the introduction of activated coagulation factor XI inhibitors, which have fewer bleeding effects, the use of DPI in patients with atherosclerotic cardiovascular diseases could be extended.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e14"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/94/ecr-18-e14.PMC10316355.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9793294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control. 蛋白转化酶枯草杆菌素/可欣9型抑制:脂质控制的一大进步。
IF 3
European Cardiology Review Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.14
Rishi Rikhi, Michael D Shapiro
{"title":"Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control.","authors":"Rishi Rikhi,&nbsp;Michael D Shapiro","doi":"10.15420/ecr.2023.14","DOIUrl":"https://doi.org/10.15420/ecr.2023.14","url":null,"abstract":"<p><p>The breakthrough discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) 20 years ago revolutionised the current understanding of cholesterol homeostasis. Genetic studies have shown that gain-of-function mutations in <i>PCSK9</i> lead to elevated LDL cholesterol and increased risk of atherosclerotic cardiovascular disease, while loss-of-function mutations in <i>PCSK9</i> result in lifelong low levels of circulating LDL cholesterol and dramatic reduction in atherosclerotic cardiovascular disease. Therapies inhibiting PCSK9 lead to a higher density of LDL receptor on the surface of hepatocytes, resulting in greater ability to clear circulating LDL. Thus far, randomised controlled trials have shown that subcutaneous fully human monoclonal antibodies targeting PCSK9, evolocumab and alirocumab, and <i>PCSK9</i> silencing with inclisiran result in drastic reductions in LDL cholesterol. Additionally, several novel strategies to target PCSK9 are in development, including oral antibody, gene silencing, DNA base editing and vaccine therapies. This review highlights the efficacy, safety and clinical use of these various approaches in PCSK9 inhibition.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e45"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/a6/ecr-18-e45.PMC10345936.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Importance of Oxidative Stress Biomarkers and the Need of Antioxidant Therapy in the Control of Cardiac Arrhythmias. 氧化应激生物标志物的重要性及抗氧化治疗在心律失常控制中的必要性。
IF 3
European Cardiology Review Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO15
Maria Cristina Bezna, Suzana Danoiu, Marinela Bezna, Iulia-Andreea Voisneanu, Amelia Genunche-Dumitrescu, Octavian Istratoaie
{"title":"The Importance of Oxidative Stress Biomarkers and the Need of Antioxidant Therapy in the Control of Cardiac Arrhythmias.","authors":"Maria Cristina Bezna,&nbsp;Suzana Danoiu,&nbsp;Marinela Bezna,&nbsp;Iulia-Andreea Voisneanu,&nbsp;Amelia Genunche-Dumitrescu,&nbsp;Octavian Istratoaie","doi":"10.15420/ecr.2023.18.PO15","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO15","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e32"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/d4/ecr-18-e32.PMC10316352.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信